Bayer Aktien Stock Price, News & Analysis

Bayer has appointed William Dodero as the new U.S. General Counsel effective January 1, 2023. He succeeds Scott Partridge, who is leaving to focus on dispute resolution. Dodero brings 20 years of experience with Bayer and has successfully led the company's legal strategies in various areas, including the Roundup litigation. He will oversee compliance, corporate law, and other legal functions. Patrick Lockwood-Taylor, President of Bayer U.S., expressed enthusiasm about Dodero's leadership amid growing challenges in food security and healthcare.

Prime Medicine has appointed Wendy Chung, Kaye Foster, and Michael A. Kelly to its board of directors. These new members bring extensive experience in research and development, financial management, and human resources, enhancing the company’s leadership. CEO Keith Gottesdiener emphasized the importance of a strong team to advance their novel Prime Editing technology, which aims to provide one-time curative genetic therapies for a wide range of diseases. This appointment is expected to support the company’s goal of delivering potentially life-changing treatments.

The Fears Nachawati law firm is urging a federal judge to reject a proposed settlement between Bayer (OTCMKTS: BAYZF, BAYRY) and consumers seeking reimbursement for Roundup. They allege that the settlement could limit cancer victims' ability to seek justice. Representing over 4,000 cancer victims, the firm raises concerns about collusion due to generous legal fees and ambiguous language that may protect Monsanto from damages. Previous attempts at a similar settlement were blocked by the JPML. Notably, several trials have found that Roundup exposure causes cancer, leading to multimillion-dollar verdicts.

A panel has denied Bayer's request to settle lawsuits linked to its Roundup herbicide, impacting ongoing multidistrict litigation affecting thousands of cancer victims. The Judicial Panel on Multidistrict Litigation ruled on Oct. 8, transferring the case to U.S. District Judge Vince Chhabria, who has previously rejected settlements from Monsanto. Legal representatives criticized Bayer's actions as an attempt to limit justice for cancer victims, emphasizing the judge's capability to handle such cases. Three prior bellwether trials have ruled against Bayer, affirming that Roundup exposure caused cancer.

Bayer's impact investment arm, Leaps by Bayer, has co-led a USD 15 million Series A investment in Andes, an innovator in seed treatment technology. This investment aims to advance Andes' 'Microprime' technology, which reduces reliance on synthetic fertilizers by enhancing nitrogen fixation from the air. The initial Microprime corn seeds provide 30 to 50 lbs/acre of nitrogen. Additionally, Andes is developing carbon capture solutions to sequester CO2, targeting gigatons of annual emissions reduction. The funding supports scaling these eco-friendly innovations in the U.S. and South America.

Innovative Partnerships Group (IPG) has launched a new division, IPG Health, aimed at enhancing corporate partnerships in the healthcare and life sciences sectors. This division will be led by Eric Marton, a seasoned expert with over 25 years in healthcare and venture capital. Marton will drive growth and expand IPG's technology portfolio, working with clients including Bayer (BAYRY), eHealth (EHTH), and Herbalife (HLF). IPG Health focuses on creating innovative financing solutions and transforming vendor relationships into sustainable partnerships.

Fears Nachawati Law Firm celebrates a significant ruling from U.S. District Judge Vince Chhabria that rejected Bayer AG's proposed settlement concerning Roundup cancer claims. Judge Chhabria criticized the settlement for being unfair and limiting future lawsuits from cancer victims exposed to Roundup, developed by Monsanto, acquired by Bayer in 2018. This ruling allows over 4,000 current and future cancer victims to pursue individual trials, holding Bayer accountable for potential damages related to non-Hodgkin lymphoma cases. The multidistrict litigation continues in California's federal court.

On May 19, 2021, lawyers for cancer victims urged a federal judge to reject a settlement proposal that would enable Bayer AG to continue selling Roundup while limiting future legal claims for non-Hodgkins lymphoma diagnoses. The proposal, criticized during a hearing by U.S. District Judge Vince Chhabria, would require exposed individuals to forfeit rights to sue if diagnosed later. Trial lawyers represent over 4,000 affected individuals and remain hopeful that the court will deny Bayer's request. A ruling on the settlement is expected later.